Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 3Thoracic 2Genitourinary 2Other solid neoplasm 1Head & Neck 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Thyroid Neoplasms 1Skin Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Lung Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

Carboplatin 542Pemetrexed 392pembrolizumab 372Cisplatin 356Paclitaxel 285Docetaxel 240Gemcitabine 168Nivolumab 158Erlotinib Hydrochloride 147Bevacizumab 114atezolizumab 104osimertinib 99durvalumab 92Etoposide 90Gefitinib 68130-nm albumin-bound paclitaxel 65Cetuximab 64Ipilimumab 60Drug Therapy 51Topotecan 48Injections 44Afatinib 41tislelizumab 40Cyclophosphamide 39Albumin-Bound Paclitaxel 37Vinorelbine 36Crizotinib 34cemiplimab 31icotinib 26Radiotherapy 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × IT-101 × Thoracic × Clear all
NCT00333502 2020-05-28

Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors

Lumos Pharma

Phase 1/2 Completed
62 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Skin Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms

NCT01380769 2020-05-28

A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer

Lumos Pharma

Phase 2 Completed
157 enrolled 9 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡